Business Wire

The Poseidon Foundation Announces Fundraising Timetable Ahead of Platform Launch

Del

The Poseidon Foundation (“Poseidon”) is pleased to announce the timetable for its year-long public fundraising phase which encompasses three token sales ahead of the platform’s official launch in August 2019. The first token sale will launch on 16th June 2018 and will last six weeks ending 29th July 2018. The second token sale will be launched on 3rd November 2018 lasting four weeks and the third token sale will launch on 4th May 2019 for two weeks.

Poseidon is a non-profit which uses blockchain technology to integrate carbon markets into transactions at the point-of-sale, giving individuals and organisations the opportunity to rebalance their climate impact by supporting forestry conservation projects around the world when they buy and sell everyday items.

During the three sales, 18 billion OCEAN tokens will be available for purchase. OCEAN is a single utility token that provides access to carbon credits through the Poseidon platform. Using OCEAN tokens, platform users will be able to offset the unavoidable climate impact of their businesses and everyday lives. During the first raise, OCEAN will be available for purchase at a 35% discount against the token’s internal value, until 29th July using Stellar Lumens, Bitcoin, and Ethereum.

The internal value of OCEAN will be derived from an external and independent benchmark of the total value of the global carbon market, which is currently estimated to be approximately €8.64 billion. 36 billion OCEAN tokens will be issued, each with a value of €0.24. Contributors to the token sale will enjoy discounts against the launch value, as outlined in the schedule below.

As a non-profit foundation, Poseidon will use 80% of the funds raised from token sale to purchase carbon credits for the platform. The remaining funds will be used to cover operational costs, including further development of the platform, R&D and the onboarding of new pilot projects with retailers. Should contributors prefer, there will be an option to make charitable donations to Poseidon. In the case of charitable donations, 100% of the funds committed will be used to purchase carbon credits and directly support forest conservation projects in the rainforest. Laszlo Giricz, founder and CEO of Poseidon, said, “The first token sale will be the culmination of months of hard work by our talented team. Our platform is the first of its kind to truly put consumers in control of their own carbon footprint when buying anything from a cup of coffee to a litre of fuel.”

“We are already operational at Ben & Jerry’s Scoop Shop in London where we have protected over 1,500 trees in just over a month. This represents a small example of the positive environmental impact the platform could deliver across multiple retailers.”

ENDS

Notes to Editors

The three OCEAN token sales will be scheduled as follows:

First token sale

 

Second token sale

 

Third token sale

Duration: 6 weeks

Duration: 4 weeks

Duration: 2 weeks

Start: 16 June 2018, noon GMT

Start: 03 November 2018, noon GMT

Start: 04 May 2019, noon GMT

End: 29 July 2018, 11:59 PM GMT

End: 09 December 2019, 11:59 PM GMT

End: 19 May 2019, 11:59 PM GMT

Token Discount: 35%

Token Discount: 20%

Token Discount: 5%

Token Price: €0.1560

Token Price: €0.1920

Token Price: €0.2280

About Poseidon

Poseidon is a non-profit foundation that empowers individuals to rebalance the climate impact of their lifestyle choices with a breakthrough approach. Using blockchain technology, it integrates carbon markets into everyday retail transactions at the point-of-sale and allows users to track the positive impact of their transactions on individual forest conservation projects. This will transform people’s relationship to their carbon footprint, encourage vital behavior change and unlock the considerable growth potential of carbon markets to effectively address climate change.

To find out more about Poseidon - https://poseidon.eco/

Contact information

Hawthorn Advisors for Poseidon
Ed Jones-Davies
Email: e.jones-davies@hawthornadvisors.com
Tel: +44 (0) 20 3745 4977

Om Business Wire

Business Wire
Business Wire
24 Martin Lane
EC4R 0DR London

+44 20 7626 1982http://www.businesswire.co.uk

(c) 2018 Business Wire, Inc., All rights reserved.

Business Wire, a Berkshire Hathaway company, is the global leader in multiplatform press release distribution.

Følg saker fra Business Wire

Registrer deg med din epostadresse under for å få de nyeste sakene fra Business Wire på epost fortløpende. Du kan melde deg av når som helst.

Siste saker fra Business Wire

Pierre Fabre & Array BioPharma Announce a 62% Observed OS at One Year from the Phase 3 BEACON CRC Safety Lead-In of the Combination of Encorafenib, Binimetinib and Cetuximab in BRAF-Mutant CRC at the ESMO GI Congress23.6.2018 11:00Pressemelding

Not intended for UK- and US-based media Pierre Fabre and its partner Array BioPharma Inc. today announced updated safety and efficacy results, including OS, from the safety lead-in of the Phase 3 BEACON CRC trial evaluating the triplet combination of encorafenib, a BRAF inhibitor, binimetinib, a MEK inhibitor and cetuximab, an anti-EGFR antibody, in patients with BRAF V600E -mutant metastatic colorectal cancer (CRC). The results showed that, at the time of analysis, the OS data were fully mature through 12.6 months and that the median OS had not yet been reached. The one-year overall survival rate for this cohort was 62%. These data were presented in an oral presentation on Saturday, June 23, at the ESMO 20th World Congress on Gastrointestinal Cancer in Barcelona, Spain. The median progression-free survival (mPFS) for patients treated with the triplet was 8 months [95% CI 5.6-9.3] and is similar between patients receiving one prior line of therapy and patients receiving two prior lines

Compelling Data for LONSURF® (trifluridine/tipiracil) in Metastatic Colorectal Cancer Presented at ESMO’s World Congress on Gastrointestinal Cancer by Servier and Taiho23.6.2018 08:10Pressemelding

Servier and Taiho Pharmaceutical Co., Ltd. today announced that the TASCO-1 trial demonstrated promising results for LONSURF® (trifluridine/tipiracil) in combination with bevacizumab in patients with previously untreated metastatic colorectal cancer (mCRC) who are not suitable for intensive treatment, with a median progression-free survival (PFS) of 9.2 months (ranging from 7.6 to 11.5 months). A second non-comparative arm in the trial, evaluated the outcome of patients treated with the current standard of care of capecitabine in combination with bevacizumab. The median PFS of this arm was 7.8 months (ranging from 5.5 to 10.1 months). “Colorectal cancer is the third most common cancer in the world. While there has been some progress in treatment, there are still few options for patients with metastatic disease who are not suitable for intensive treatment,” said Professor Eric Van Cutsem, Head of Digestive Oncology at the University of Leuven, Belgium. “These compelling results suggest

Softomotive and Accelerate RPA Partner to Help Enterprises Achieve Faster Time to Value from RPA22.6.2018 15:13Pressemelding

Softomotive, a world–class Robotic Process Automation (RPA) technology provider offering best time to value and affordability for all sizes and types of enterprises, is pleased to announce a strategic partnership with AccelerateRPA, a high calibre professional services provider of trained and certified RPA Consultants within Robotic Process Automation. This partnership means that customers and end users of Softomotive’s software, will have additional knowledgeable and professional guidance available to help achieve significant value quickly from their investment in RPA. Companies who are looking to implement Softomotive’s RPA product suite (WinAutomation and ProcessRobot software) will now have direct access to AccelerateRPA’s highly skilled consultants and Developers. Further, AccelerateRPA has also become a licensed reseller of Softomotive’s products, offering customers a single point of contact for delivering both RPA software and services. Ashley Hudson, Director of AccelerateRPA,

Ascend Performance Materials Announces Price Increase for Intermediate Materials22.6.2018 14:00Pressemelding

Ascend Performance Materials announced today a price increase for its intermediate materials. The price increase will take effect globally on July 1, 2018, and includes the following terms: Material Price Increase Terms Hexamethylene diamine (HMD) $0.17/lb. • As contracts allow. • Non-contract business – price determined on an order-by-order basis. Acrylonitrile (AN) $0.20/lb. • As contracts allow. • Non-contract business – price determined on an order-by-order basis. Customers should contact their local sales representative for additional information. About Ascend Performance Materials Ascend Performance Materials is a global premium provider of high-quality plastics, fibers and chemicals and is the world’s largest integrated producer of PA66 resin. Headquartered in Houston, Texas, Ascend has eight global locations, including five fully-integrated manufacturing facilities located in the southeastern United States, all dedicated to the innovation and safe production of nylon 6,6. With

Different Countries, Different Customs: Get Ready for the Motorbike Holidays with Moto-tyres.co.uk22.6.2018 13:41Pressemelding

Pack your bags, close the boot and get away on holiday? When you start your holidays on a motorcycle, you usually have to consider a few things more when getting ready for your trip. The right preparation is therefore a must. So that nothing stands in the way of a smooth journey, Moto-tyres.co.uk has put together some tips for your next trip. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20180622005345/en/ Different countries, different customs: get ready for the motorbike holidays with Moto-tyres.co.uk (Photo: Business Wire) Whether a weekend trip or extended adventure, it all depends on the right equipment. Functional clothing, protectors and rain protection are a must on long trips. Wearing a suitable motorcycle helmet is a legal requirement almost everywhere. However, there are also very different rules and regulations for motorbike equipment and accessories depending on the destination, and you should familiarise yoursel

Boehringer Ingelheim bolsters biologics research and development with 230 million euro investment in new development center22.6.2018 12:00Pressemelding

Today Boehringer Ingelheim announced a 230 million euro investment into a new Biologicals Development Center (BDC) at the company’s Research and Development site in Biberach, Germany during the foundation stone laying for the new center. “The BDC is another key building block supporting the company’s long-term strategy for increasing the pipeline’s share of biologicals. This is particularly driven by two of our core areas, immune oncology and immunology,” says Dr. Fridtjof Traulsen, Corporate Senior Vice President Development at Boehringer Ingelheim. “The share of new biological entities in Boehringer Ingelheim’s research pipeline has been consistently increasing over the past few years and has now reached forty percent.” The BDC will help to maximize synergies by integrating biologicals analytical and process development as well as manufacturing for clinical studies into one seamless unit, while at the same time increasing development capacity. Following a staggered launch beginning i